The Oxford Astrozenica Vaccine Generates a Higher Concentration of Neutralizing Antibodies

Since the beginning oft he pandemic, researchers have searched for a biomarker which indicates immune protection from COVID-19 known as a correlate of protection. Now, the team developing the Oxford–AstraZeneca COVID-19 vaccine have published the first results of their so-called 'breakthrough study' which indicated puts forwards thresholds of neutralising antibodies that they suggest correlate with protection. The hope is that, should these results be confirmed, such biomarkers could speed up the development of new vaccines, and provide better ways to monitor the efficacy of tweaked vaccine aimed at fighting variants.

News: Scientists identify long-sought marker for COVID vaccine success

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.